Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC). Update March 2022

Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC). Update March 2022. Oncology Fact Sheet Nr. 74.

[thumbnail of Oncology Fact Sheet Nr.74_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
118kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WJ Urogenital system > WJ 300-378 Kidney
Language:	English
Series Name:	Oncology Fact Sheet Nr. 74
Deposited on:	17 Jan 2022 16:36
Last Modified:	16 May 2022 09:33

Repository Staff Only: item control page